QRxPharma Limited (QRX)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: QRxPharma Limited
Stock Code: QRX
Website: www.qrxpharma.com
GICS Sub-Industry: Pharmaceuticals
Market Cap ($M): 3
Equiv. Shares (M): 164

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
$ 0.016 $ 0.014 $ 0.016 $ 0.014 $ 0.016 554,829 0%

Current Broker Consensus Recommendation more
Recommendation: Strong Buy (1)
Recommendation Date: 20th Aug 2014
Brokers Surveyed: 1

Company Overview

Business Description:
QRxPharma Limited (QRX) is a commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and abuse prevention products. QRX conducts its operations in Australia.

Strategy Analysis:
In 2012, QRX plan to implement pre-launch messaging strategy, identify key geographic areas of concentration, implement MoxDue pre-launch promotional message and begin recruitment of additional Actavis territory managers. Beyond 2012, QRX strategy is to expand the sales force to 150-200. QRxPharma reported net loss of $5.21m, up 7.87% for the half-year ended 31 December 2012. Revenue from ordinary activities were $2.24m, down 26.89% from last year. Basic and Diluted EPS were (3.6) cents compared to (4) cents last year. The net operating cash outflow was $6.04m compared to an outflow of $1.92m in the pcp. No dividend was declared.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014  A -13.3 -8.5 -- 0.0 0.0 0.0 --
2013  A -10.1 -7.0 -- 0.0 0.0 0.0 --
2012  A -16.0 -11.2 -- 0.0 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
Acrux Limited (ACR) $136 M 3.0384 -0.6083 0.1581 4.8512 12.3860 10.6955 9.82 8.94 8.60
Mayne Pharma Group (MYX) $753 M 1.0457 -0.2428 1.2152 30.6709 40.5063 18.2857 0.00 0.00 0.00
QRxPharma (QRX) $2 M -- -- -- -- -- -- 0.00 -- --

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
QRX -- -- 0.29 -- 4.21
Market 0.88 16.6 1.30 2.42 1.60
Sector 0.81 15.7 2.56 1.26 7.77

Name Position Start Date
Mr Bruce Alan Hancox Non-Executive Director 09 July 2014
Dr Richard Treagus Non-Executive Director 09 July 2014

Name Position
Edward Rudnic Chief Executive Officer
Chris Campbell Chief Financial Officer,Company Secretary
Beth A Burnside Senior Vice President Regulatory Affairs and Compliance
M. Janette Dixon Vice President Global Business Development

Substantial Shareholders
Holding Name
15,653,120 (9.53%) Walker Group Holdings Pty Limited
20,854,104 (12.70%) Allan Gray Australia Pty Ltd

Calendar of Events
Date Event
24 February 2016 Report (Interim)
25 September 2015 Report (Annual)
26 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Trading Forex

An educational booklet with information on becoming a successful trader, including essentials you need to learn and the skills you need to develop.

More details...


Markets melt up

By Michael McCarthy (chief market strategist, CMC Markets) 19/12/2014 | Traders and investors caught short heading into the FOMC scrambled for cover in Europe and the US, in many cases driving indices to their best one day performance for 2015.

Aussie Investors take their foot off the accelerator

By Betty Lam (Sales Trader, CMC Markets) 18/12/2014 | Lead by the Fed-fervour offshore, Australians shares jumped on the Yellen cheer wagon. The material and energy stocks were back in vogue as both sectors gained over 3% in morning trade.

Fed Feeds Frenzy

By Michael McCarthy (chief market strategist, CMC Markets) 18/12/2014 | In spite of a frenzied pre-mortem, a benign statement from the US Federal Reserve‚Äôs Open Market Committee and steadying commodity markets drove investors back into share markets overnight. A calmer, stronger ruble helped offset European growth fears, highlighted in the overnight session by further declines in inflation.

Household brands Woolworths and Telstra Heavy Lifting

By Betty Lam (Sales Trader, CMC Markets) 11/12/2014 | Offshore jitters sent ripples through to Australian stocks. The open saw the local equities take 65 points off the index, catalysed by a mass-exit in energy stocks, yet again.

Steady open as Woodside investors wait on details of possible Wheatstone acquisition

By Ric Spooner (Chief Market Analyst, CMC Markets) 10/12/2014 | Yesterday‚Äôs news on Greek politics and China‚Äôs bond market came at a time when US and European stock markets have extended rallies and pushed valuations higher. This makes those markets vulnerable to downward corrections as profit takers act to avoid missing out.

MYEFO and Lima - December could be nasty.

BR Securities Australia Pty Ltd 2/12/2014 | December 2014 could go down as a nasty moment in Australian finance. MYEFO will reveal a deteriorating budget deficit and the UNFCCC meeting in Lima, Peru will provide the agreement, to be ratified in Paris in 2015, on how much (or little) CO2 is to be allowed into the atmosphere from 2020.


Sponsored Links